your market intelligence analyst
Search Results
Edit Save
163 results
Ovarian Cancer News Today 04/01/2020 12:00
Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with platinum-resistant ovarian cancer, early results from a Phase 2 trial show. Full analysis of the study’s first part is ongoing. However, the treatment’s developer, NuCana, has decided not to continue with a planned second part to focus on trials in other cancers. Acelarin […]. .
Ovarian Cancer News Today 03/25/2020 13:30
The immunotherapy candidate GEN-1 has shown encouraging results in patients newly diagnosed with advanced ovarian cancer, according to initial results of the OVATION 2 study. Adding GEN-1 to neoadjuvant chemotherapy (given before surgery to shrink tumors) increased the proportion of patients with complete removal of their tumors through surgery. GEN-1, developed by Celsion Corporation, consists of […]. .
Ovarian Cancer News Today 03/23/2020 08:00
Disrupting genes essential for the cellular recycling process known as autophagy increases the frequency of mutations during cell division and promotes the formation of ovarian cancer tumors, a study in mice has found. These findings support further investigation into the process of autophagy, which is often abnormal in ovarian cancer patients, as a potential target […]. .
Ovarian Cancer News Today 03/18/2020 08:00
Four projects chosen by the National Comprehensive Cancer Network’s (NCCN) Oncology Research Program will explore ways to use technology to improve care for advanced ovarian cancer patients. Funded by AstraZeneca, the two-year projects will begin the third quarter of this year. They are expected to provide measurable outcome steps, and be reproducible, scalable and swiftly […]. .
Ovarian Cancer News Today 03/13/2020 08:00
CytoDyn has been cleared by an institutional review board to start a Phase 2 trial testing its investigational therapy leronlimab (PRO 140) to treat about 22 different solid cancers, including ovarian cancer. Leronlimab is an antibody that blocks C-C motif chemokine receptor 5 (CCR5), a protein present in high levels in several cancers. CCR5 acts like […]. .
Ovarian Cancer News Today 03/11/2020 08:00
Including donations from more than 1 million individuals across all 50 states, 13-year-old Cycle for Survival has raised more than $250 million to date to fight rare malignancies such as ovarian cancer. The amount exceeds a major fundraising milestone. All proceeds from the annual high-energy event go toward research led by the Memorial Sloan Kettering […]. .
Ovarian Cancer News Today 03/09/2020 08:00
Anixa Biosciences and Moffitt Cancer Center have completed the development and validation of a new viral vector designed to improve the efficacy of their immunotherapy candidate for ovarian cancer, based on CAR T-cell technology. The vector’s manufacturing is now ongoing under Good Manufacturing Practice conditions — those ensuring that medicines are consistently produced in high […]. .
Ovarian Cancer News Today 03/02/2020 08:00
The inflammatory protein interleukin-6 (IL-6) appears at significantly higher levels in the blood of ovarian cancer patients in comparison with women with benign masses in the ovaries and healthy women, new research has found. Thus, determining IL-6 levels may supplement conventional tests and biomarker assessments used to diagnose the disease, the findings suggest. IL-6 also […]. .
Ovarian Cancer News Today 02/28/2020 08:00
Treatment with Compugen‘s immune checkpoint inhibitor COM701, either alone or in combination with Opdivo (nivolumab), is well-tolerated in people with advanced solid tumors, including ovarian cancer, early Phase 1 trial results show. The findings were presented in a poster, “A Phase 1 Study Evaluating COM701 Monotherapy and in Combination with Nivolumab in Patients With Advanced Solid Malignancies,” […]. .
Ovarian Cancer News Today 02/24/2020 08:00
The Australian Cancer Council NSW has awarded its annual $3.75 million Translational Program Grant to a University of Sydney research team to explore better ways to personalize ovarian cancer treatments. For the next five years, investigators led by professor Anna deFazio, PhD, the university’s Sydney West Chair in Translational Cancer Research, will work to develop […]. .
Ovarian Cancer News Today 02/17/2020 08:00
Analysis of cells in the fallopian tube, from which most ovarian cancers develop, can help classify ovarian cancer subtypes, with potential implications for cancer prognoses and treatment strategies, a new study shows. The study, “The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells,” was published in Cancer […]. .
Ovarian Cancer News Today 02/12/2020 08:00
Immune responses in women with advanced ovarian cancer being treated with DPX-Survivac in clinical trials continue to support the immunotherapy’s potential, alone or in combination, to be effective in this patient population. DPX-Survivac, developed by IMV, is being seen to elicit significant anti-tumor responses in these ovarian cancer patients. It works by inducing strong and sustained survivin-specific immune […]. .
Ovarian Cancer News Today 02/07/2020 08:00
Researchers at Northwestern University have identified and mapped the location of structural proteins within pig’s ovaries, which closely resemble human ovaries. This will help the development of an ovary-specific bio-ink that can be used to three-dimensionally (3-D) print artificial, implantable human ovaries that will allow infertile women to bear children. “This is a huge step […]. .
Ovarian Cancer News Today 01/31/2020 08:00
Nami Therapeutics is developing a new form of targeted therapy that aims to be more effective and less toxic than other treatments for advanced forms of ovarian cancer. The new therapy uses small particles (nanoparticles) that are specifically designed to deliver a toxic radioactive compound called holmium-166 (Ho-166) to ovarian cancer cells, while leaving healthy […]. .

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities


Strategic Scenarios